ABLE Human Motion

ABLE Human Motion operates in medical devices, neurorehabilitation, robotics, and assistive technology, with a specific emphasis on lightweight and affordable exoskeletons for people with mobility impairments. Its ABLE Exoskeleton is designed to help paraplegic users stand, walk, and sit, while also serving clinicians in rehabilitation settings. In market context, it addresses a segment that includes established exoskeleton developers such as Ekso Bionics and ReWalk Robotics, as well as newer European developers such as Wandercraft; however, public information available for ABLE does not support a quantified market-share comparison. Its stated differentiation is the combination of affordability, low weight, quick adjustment, and an integrated medical-device development approach spanning clinical operations, mechatronics, software, firmware, control systems, manufacturing, quality, and regulatory affairs. Six granted patents and four registered trademarks indicate a developing intellectual-property base. The company remains an active private venture with approximately $2.28 million in disclosed funding across grants and seed financing, placing it at an earlier capital stage than several better-funded commercial peers.

ABLE Human Motion was founded in Barcelona on Oct 30, 2018 and progressed from early support from EIT Health and EISMEA into a larger 2019 seed round of approximately $785,023, followed by a $560,948 seed round in 2020. Grants from CDTI, the Ministry of Economy and Competitiveness, CaixaImpulse, and Horizon 2020 brought disclosed structured funding to approximately $2.28 million through Apr 1, 2021. The company’s trajectory then shifted from financing milestones toward product, intellectual-property, and organizational development. The ABLE Exoskeleton became the central product, targeting clinical neurorehabilitation and daily ambulation for wheelchair users. Patent activity in 2023 covered assisted-walking interfaces and transfer systems, while a 2025 filing addressed powered exoskeleton control during sit-to-stand movement. Team growth to 35 people in 2025 is a material operating inflection point for a company spanning medical-device engineering, production, regulatory work, clinical operations, and customer support. The 2025 EIT Venture Award and Public Award provide additional recognition, although public information does not establish commercial revenue, shipment volume, or a new financing event after 2021.